The effects of thymoquinone and genistein treatment on telomerase activity, apoptosis, angiogenesis, and survival in thyroid cancer cell lines

Öztürk, Sibel; Alp, Ebru; Sağlam, Atiye Seda Yar; Konac, Ece; Menevse, Emine Sevda

doi:10.4103/0973-1482.202886

Cited by 28 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the same research it is also demonstrated that it affects the angiogenesis by acting on NF-κB. Some reports are also available for antiangiogenic activity of TQ with the same VEGF mechanistic activity in different cell lines (Peng et al, 2013, Paramasivam et al, 2012, Kundu et al, 2014, ElKhoely et al, 2015, Ozturk et al, 2018). Inhibition of VEGF not only directly inhibits the angiogenesis but also it causes the necrosis in that particular area of tumor development and in this way it may hamper the blood vessel formation (Ahmad et al, 2019).…”

Section: Thymoquinone and Angiogenesismentioning

confidence: 89%

Thymoquinone (2-Isopropyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects

Ahmad

Mishra

Vyawahare

et al. 2019

Saudi Pharmaceutical Journal

120

View full text Add to dashboard Cite

show abstract

Section: Thymoquinone and Angiogenesismentioning

confidence: 89%

Thymoquinone (2-Isopropyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects

Ahmad

Mishra

Vyawahare

et al. 2019

Saudi Pharmaceutical Journal

120

View full text Add to dashboard Cite

show abstract

“…278 Genistein has also been reported to inhibit glioblastoma, head and neck and other cancers in a telomerase-dependent manner. [279][280][281] In addition, Li et al discovered genistein-induced telomerase repression due to crosstalk between genetic and epigenetic mechanisms. They indicated that genistein decreased the expression of DNA methyltransferases DNMT1, DNMT3a, and DNMT3b, leading to the hypomethylation of the E2F-1 (repressor) recognition site in hTERT and increased binding of E2F-1 and hTERT.…”

Section: Non-oncology Drugs In Drug Repurposingmentioning

confidence: 99%

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang

Zhou

Xie

et al. 2020

Sig Transduct Target Ther

391

315

View full text Add to dashboard Cite

Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing, the development of old drugs for new therapeutic purposes. This strategy with a cost-effective way offers a rare opportunity for the treatment of human neoplastic disease, facilitating rapid clinical translation. With an increased understanding of the hallmarks of cancer and the development of various data-driven approaches, drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target-defined antineoplastic compounds. The "treasure trove" of non-oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer. Indeed, different from targeted drugs, these old generic drugs, usually used in a multi-target strategy may bring benefit to patients. In this review, aiming to demonstrate the full potential of drug repurposing, we present various promising repurposed non-oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono-or drug combination therapy. We also summarize approaches used for drug repurposing and discuss the main barriers to its uptake.

show abstract

“…In addition, in vitro invasion assay and gelatin zymography using HSC-3 cells have also shown a decreased expression of VEGF. More recently, using thyroid cancer cells, a group of investigators revealed the downregulation of VEGF-A expression along with human telomerase reverse transcriptase, PTEN, NF-κB, and p21 (Ozturk et al, 2018). All these antiangiogenic molecular mechanistic insights have been summarized in Figure 6 .…”

Section: Molecular Mechanisms Of Action Of Genisteinmentioning

confidence: 99%

Molecular Mechanisms of Action of Genistein in Cancer: Recent Advances

et al. 2019

View full text Add to dashboard Cite

Background: Genistein is one among the several other known isoflavones that is found in different soybeans and soy products. The chemical name of genistein is 4′,5,7-trihydroxyisoflavone. Genistein has drawn attention of scientific community because of its potential beneficial effects on human grave diseases, such as cancer. Mechanistic insight of genistein reveals its potential for apoptotic induction, cell cycle arrest, as well as antiangiogenic, antimetastatic, and anti-inflammatory effects. Objective: The purpose of this review is to unravel and analyze various molecular mechanisms of genistein in diverse cancer models. Data sources: English language literature was searched using various databases, such as PubMed, ScienceDirect, EBOSCOhost, Scopus, Web of Science, and Cochrane Library. Key words used in various combinations included genistein, cancer, anticancer, molecular mechanisms prevention, treatment, in vivo, in vitro, and clinical studies. Study selection: Study selection was carried out strictly in accordance with the statement of Preferred Reporting Items for Systematic Reviews and Meta-analyses. Data extraction: Four authors independently carried out the extraction of articles. Data synthesis: One hundred one papers were found suitable for use in this review. Conclusion: This review covers various molecular interactions of genistein with various cellular targets in cancer models. It will help the scientific community understand genistein and cancer biology and will provoke them to design novel therapeutic strategies.

show abstract

The effects of thymoquinone and genistein treatment on telomerase activity, apoptosis, angiogenesis, and survival in thyroid cancer cell lines

Abstract: Based on these results, two agents can be good options as potential phytochemotherapeutics against TCCs.

Cited by 28 publications

References 27 publications

Thymoquinone (2-Isopropyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects

Thymoquinone (2-Isopropyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects

Overcoming cancer therapeutic bottleneck by drug repurposing

Molecular Mechanisms of Action of Genistein in Cancer: Recent Advances

Contact Info

Product

Resources

About